Teva Pharmaceutical Industries logo

Teva Pharmaceutical Industries(NYSE) TEVA

Market Cap$47.60BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2003)-25%
5 Year+303%
1 Year+110%
1 Month+5%
$40.42
-1.05%
-0.43Today
Teva Pharmaceutical Industries last closing stock price
MetricPriceDate
Last closeUSD 40.852026-10-20
Teva Pharmaceutical Industries stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-0.97%USD 41.252026-10-13
1 month+4.8%USD 38.982026-09-18
3 month+35.49%USD 30.152026-07-22
Year to date+30.89%USD 31.212025-12-31
1 year+110.35%USD 19.422025-10-20
3 year+403.08%USD 8.122023-10-20
5 year+302.86%USD 10.142021-10-21
Since inception-25.46%USD 54.802003-08-12

Teva Pharmaceutical Industries Financials at a Glance

Market Cap

$47.60BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$17.31B

Net Income (TTM)

$706.00M

EPS (TTM)

$0.60

P/E Ratio

68.11

Dividend

$0.00

Beta (Volatility)

0.90 (Low)

Price

$40.42

Volume

817,120.998

Open

$40.18

Previous Close

$40.85

Daily Range

$39.50 - $40.24

52-Week Range

$18.83 - $42.02

Estimated Earnings Date

Nov 3, 2026

TEVA News

biotech pharma researchers talk lab-1200x800-5b2df79

Teva Pharmaceutical: 3 Numbers That Explain This Generic-Drug Turnaround

Thomas NielSep 29, 2026

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited is a global pharmaceutical company engaged in the development, manufacturing, and marketing of a wide range of generic, specialty, and biopharmaceutical products. With a strong presence in North America, Europe, and various international markets, Teva focuses on therapeutic areas such as central nervous system disorders, pain management, respiratory conditions, and oncology.

Products and Services
  • Generic and specialty pharmaceuticals across various therapeutic areas
  • Active pharmaceutical ingredients (APIs) for diverse applications
  • Innovative long-acting injectable formulations in collaboration with MedinCell
Growth Outlook
  • Recent quarterly revenue of $4.14 billion indicates strong market demand
  • Focus on expanding oncology and respiratory product lines to capture market share
  • Strategic partnerships aim to enhance product offerings and innovation
Financial Highlights
  • Trailing twelve months (TTM) revenue of $16.4 billion reflects stable performance
  • Operating income margin of 3.6% shows potential for operational efficiency
  • Net income of -$576 million in Q2 2026 highlights challenges in profitability
Teva Pharmaceutical Industries Limited has established itself as a key player in the pharmaceutical industry, with a diverse portfolio that addresses critical health needs. The company's commitment to innovation and strategic partnerships positions it well for future growth, despite recent financial challenges. Investors may find the ongoing developments in product offerings and market expansion efforts noteworthy as they evaluate the company's potential.
AI Generated • Oct 16, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

33,346

CEO

Richard Francis

Website

www.tevapharm.com

Headquarters

Tel Aviv, TA 6944020, IL

TEVA Financials

Key Financial Metrics (TTM)

Gross Margin

52.47%

Operating Margin

11.45%

Net Income Margin

4.08%

Return on Equity

9.07%

Return on Capital

8.53%

Return on Assets

1.77%

Earnings Yield

1.47%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$47.60BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

1.17B

Volume

817.12K

Avg. Volume

5.69M

Financials (TTM)

Gross Profit

$9.09B

Operating Income

$1.98B

EBITDA

$2.59B

Operating Cash Flow

$1.90B

Capital Expenditure

-$550.00M

Free Cash Flow

$1.35B

Cash & ST Invst.

$3.66B

Total Debt

$16.87B

Teva Pharmaceutical Industries Performance Analysis

Teva Pharmaceutical Industries annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 14,914,000,000-5.9%
20232023-12-31USD 15,848,000,0006.3%
20242024-12-31USD 16,510,000,0004.2%
20252025-12-31USD 17,323,000,0004.9%
Teva Pharmaceutical Industries sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-307.3%
Q42025-12-315.2%
Q12026-03-31-15.5%
Q22026-06-304.0%
Teva Pharmaceutical Industries annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -2.20N/A
20232023-12-31USD -0.50-77.3%
20242024-12-31USD -1.45190.1%
20252025-12-31USD 1.21N/A
Teva Pharmaceutical Industries sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-3054.2%
Q42025-12-3110.8%
Q12026-03-31-24.4%
Q22026-06-30-258.1%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$4.14B

-0.8%

Gross Profit

$2.15B

+2.4%

Gross Margin

51.98%

N/A

Market Cap

$47.60BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.49M

N/A

Employees

32,008

N/A

Net Income

-$576.00M

-304.3%

EBITDA

-$19.00M

-102.9%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$3.66B

+69.1%

Total Debt

$16.87B

-3.7%

Accounts Receivable

$3.49B

-2.0%

Inventory

$3.22B

-7.9%

Long Term Debt

$12.37B

-27.5%

Short Term Debt

$4.50B

+869.8%

Return on Assets

1.77%

N/A

Return on Invested Capital

8.19%

N/A

Free Cash Flow

$307.00M

+134.4%

Operating Cash Flow

$411.00M

+81.1%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
SDZNYSandoz Group AG
$94.84+1.37%
VTRSViatris Inc.
$18.57-0.43%
RDYDr. Reddy's Laboratories Limited
$13.17-0.68%
AMRXAmneal Pharmaceuticals, Inc.
$19.89+0.23%

Trending Stocks

Symbol / CompanyPricePrice Chg
SPCXSpace Exploration Technologies
$158.44+7.21%
SMCISuper Micro Computer
$36.36+11.98%
NFLXNetflix
$66.11-3.76%
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$100.11+2.62%

Questions About TEVA

What is the current price of Teva Pharmaceutical Industries?

Teva Pharmaceutical Industries is trading at $40.01 per share.

What is the 52-week range for Teva Pharmaceutical Industries?

Over the past 52 weeks, Teva Pharmaceutical Industries has traded between $18.83 and $42.02.

How much debt does Teva Pharmaceutical Industries have?

As of the most recent reporting period, Teva Pharmaceutical Industries reported total debt of $16.87B.

How much cash does Teva Pharmaceutical Industries have on hand?

Teva Pharmaceutical Industries reported $3.66B in cash and cash equivalents in its most recent financial results.

What is Teva Pharmaceutical Industries’s dividend yield?

Teva Pharmaceutical Industries does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services